TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7719750
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil (6 drops added to bath water daily for 10 days)
Study: 2189075
Drug: Enalapril, 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10-20 mg
Study: 2189075
Drug: Captopril, 50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 50-100 mg
Study: 27324141
Drug: Flatbreads with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flatbreads with 6 g GG, 4 g KM, and 15 g CPF plus 2 or 4 g GG
Study: 26206423
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (843.0 +/- 44.0 mg/day epigallocatechin gallate)
Study: 23590801
Drug: Corticosteroids (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (with immunosuppressant adjunct when corticosteroids failed)
Study: 23590801
Drug: Anti-myeloperoxidase antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-myeloperoxidase antibodies
Study: 19121573
Drug: guaifenesin 600
Normalized name: guaifenesin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: guaifenesin 600 mg (G)
Study: 19121573
Drug: benzonatate 200
Normalized name: benzonatate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzonatate 200 mg (B)
Study: 19121573
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of benzonatate 200 mg and guaifenesin 600 mg (B+G)
Study: 9540874
Drug: Natural somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural somatostatin (single bolus injection)
Study: 8126502
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg levodopa/50 mg carbidopa with 200 mg entacapone
Study: 8126502
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg levodopa/50 mg carbidopa with 800 mg entacapone
Study: 1092513
Drug: Deanol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deanol (500 mg daily)
Study: 1092513
Drug: Methylphenidate (40
Normalized name: methylphenidate (40/60 release) 15 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (40 mg daily)
Study: 27652589
Drug: Prasugrel 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 20 mg single dose
Study: 27652589
Drug: Prasugrel 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 30 mg single dose
Study: 27652589
Drug: Prasugrel 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 20 mg loading dose followed by 5 mg/day maintenance dose
Study: 27652589
Drug: Prasugrel 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 30 mg loading dose followed by 7.5 mg/day maintenance dose
Study: 21615670
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 µg (subcutaneous) twice daily
Study: 21615670
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg (oral) daily
Study: 7907097
Drug: ipsapirone (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (10.0 to 30.0 mg daily)
Study: 7907097
Drug: lorazepam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (2.0 to 6.0 mg daily)
Study: 28478185
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine liposome injectable suspension (80cc plus 1.3% liposomal bupivacaine 20cc; total injection 100cc)
Study: 28478185
Drug: Ropivacaine (periarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (periarticular injection of ropivacaine, ketorolac, morphine, and epinephrine in saline; 100cc)
Study: 21696635
Drug: EPA‐rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA‐rich fish oil supplement (1060 mg EPA plus 274 mg DHA)
Study: 21696635
Drug: DHA‐rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA‐rich fish oil supplement (900 mg DHA plus 180 mg EPA)
Study: 1675650
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine detergent solution (Group A)
Study: 7093110
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg aspirin
Study: 30552505
Drug: 6.4 g
Normalized name: BENZOCAINE 6.4 g in 32 g ORAL GEL [Mark 3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 g day−1 of sustained-release beta-alanine (CarnoSyn™, NAI, USA)
Study: 31089253
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil enriched with vitamin E (30 ml/day and 400 mg/day)
Study: 31089253
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil (30 ml/day)
Study: 31089253
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (30 ml/day)
Study: 27865620
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice (300 mL/d)
Study: 24518194
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise training in combination with conventional management (EX, n = 20)
Study: 22206079
Drug: Tri-retinol 1.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-retinol 1.1% cream
Study: 20565456
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg i.v. administration of CAT-354
Study: 20565456
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg s.c. administration of CAT-354
Study: 20565456
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg s.c. administration of CAT-354 (two 150 mg injections)
Study: 9279180
Drug: Nebulised frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised frusemide (1 mg/kg/body weight)
Study: 9279180
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide (1 mg/kg/body weight)
Study: 2423806
Drug: Indoramin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (50 mg t.i.d. per os)
Study: 23073712
Drug: Daily home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home-based exercise programme and self-care (n=11)
Study: 18204344
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment (Control)
Study: 16600940
Drug: Yogurt-plus-quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt-plus-quadruple therapy (AB-yogurt 400 mL/d for 4 weeks + quadruple therapy for 1 week)
Study: 16600940
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy only (without AB-yogurt)
Study: 14967868
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g CHO as a glucose solution at 15 min before exercise (‐15 trial)
Study: 14967868
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g CHO as a glucose solution at 75 min before exercise (‐75 trial)
Study: 14967868
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g CHO as a glucose solution 45 min before exercise
Study: 14967868
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g CHO as a glucose solution 45 min before exercise
Study: 8770990
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day dose of anti-LFA1 monoclonal antibody (MoAb) with a loading dose of 30 mg
Study: 8770990
Drug: Additional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional group receiving the same protocol (15 mg/day with a loading dose of 30 mg)
Study: 1282180
Drug: Nicorandil 20
Normalized name: nicorandil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 20 mg b.i.d. for 4 weeks
Study: 1282180
Drug: Isosorbide-5-mononitrate (MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (MN) 20 mg b.i.d. for 4 weeks
Study: 1282180
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Study: 1282180
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 10 mg t.i.d. for 2 weeks then 20 mg t.i.d. for 4 weeks
Study: 16487032
Drug: IFN in
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN in combination with amantadine or ribavirin
Study: 14761489
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion and scopolamine injection in addition to traditional therapy (gastrolavage, purgation, redox agent)
Study: 14761489
Drug: Traditional combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional combined therapy (gastrolavage, purgation, redox agent)
Study: 8970901
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of free Dpyr
Study: 6697676
Drug: Cefazolin 20
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 20 mg/kg i.v. administered with anesthesia
Study: 6697676
Drug: Cefazolin 20
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 20 mg/kg i.v. administered 'on call'
Study: 6697676
Drug: Cefoxitin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 30 mg/kg i.v. administered with anesthesia
Study: 6697676
Drug: Cefoxitin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 30 mg/kg i.v. administered 'on call'
Study: 29102648
Drug: Both radiation
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both radiation and systemic therapy
Study: 29102648
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy with radiation
Study: 24559003
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei shirota (LcS) at a dose of 16 x 10(9) CFU
Study: 24559003
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei shirota (LcS) at a dose of 8 x 10(9) CFU
Study: 22118417
Drug: Dexeryl (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexeryl (an emollient cream containing glycerol 15% and paraffin 10%)
Study: 20616762
Drug: 6-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-dose group (reduced 5-component acellular pertussis vaccine combined with tetanus toxoid and reduced diphtheria toxoid)
Study: 20616762
Drug: 5-dose group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-dose group (Tdap vaccine)
Study: 9915320
Drug: 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg etomidate
Study: 9915320
Drug: 0.050 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.050 mg/kg etomidate
Study: 9915320
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg etomidate
Study: 9915320
Drug: 0.100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.100 mg/kg etomidate
Study: 9915320
Drug: 0.200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.200 mg/kg etomidate
Study: 9915320
Drug: 0.300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.300 mg/kg etomidate
Study: 9915320
Drug: 0.050 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.050 mg/kg etomidate (pretreatment)
Study: 9915320
Drug: 0.030 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.030 mg/kg etomidate (pretreatment)
Study: 9915320
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg etomidate (pretreatment)
Study: 7751875
Drug: Single-agent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent bolus 5-FU
Study: 7751875
Drug: Unmodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unmodulated infusion regimens
Study: 7751875
Drug: 5-FU bolus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU bolus therapy
Study: 2261951
Drug: Low-dose ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ara-C in combination with 13-cis-retinoic acid (13-CRA) and 1 alpha-hydroxy-vitamin D3 (1 alpha D3)
Study: 2261951
Drug: Low-dose ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ara-C (arm A)
Study: 26041848
Drug: FX006 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX006 (10 mg)
Study: 26041848
Drug: FX006 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX006 (40 mg)
Study: 26041848
Drug: FX006 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX006 (60 mg)
Study: 26041848
Drug: Immediate-release triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release triamcinolone acetonide (40 mg)
Study: 23534896
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg/day
Study: 19164608
Drug: HMB/Arg/Lys supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/Arg/Lys supplement (beta-hydroxy-beta-methylbutyrate, L-arginine, and L-lysine)
Study: 19164608
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement (isonitrogenous)
Study: 17210383
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT) plus supervised exercise
Study: 17210383
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT) plus cilostazol
Study: 17210383
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy (BMT) plus supervised exercise plus cilostazol
Study: 16338562
Drug: Placebo (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard postoperative therapy)
Study: 12389073
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide without grapefruit juice
Study: 8665721
Drug: Intranasal lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal lysine aspirin (2000 micrograms)
Study: 2223348
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 micrograms kg‐1 i.v. with corticotrophin releasing factor 100 micrograms i.v., growth hormone releasing hormone 100 micrograms i.v., and arginine vasopressin 10 units i.m.
Study: 543907
Drug: mezlocillin (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin (slow injection)
Study: 30375661
Drug: Intensive‐intermittent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive‐intermittent music therapy (4x/week, off, 4x/week, off)
Study: 30375661
Drug: Standard spaced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard spaced protocolised music therapy (2x/week)
Study: 28800385
Drug: New paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: New paediatric valaciclovir formulation
Study: 28800385
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (crushed and suspended tablets)
Study: 25727104
Drug: 0.015% ingenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015% ingenol mebutate gel (IMB) applied daily for three consecutive days
Study: 25727104
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil (5-FU) cream applied twice a day for 4 weeks
Study: 16765271
Drug: Treatment acceptability
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment acceptability and effect among compliers
Study: 15636216
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% betaxolol
Study: 7503497
Drug: Acyclovir, 400
Normalized name: Acyclovir, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 400 mg twice daily for 70 days
Study: 1857729
Drug: Ventoline inhalation
Normalized name: Ventolin Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventoline inhalation aerosol
Study: 1857729
Drug: Orion salbutamol
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orion salbutamol inhalation aerosol
Study: 6409917
Drug: Ipodate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipodate (3 g on days 1 and 5 of fasting)
Study: 6409917
Drug: T3 (5
Normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 (5 μg every 4 h)
Study: 28229457
Drug: Hydroxy progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hydroxy progesterone injection
Study: 25683037
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) once daily
Study: 25683037
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet) once or twice daily
Study: 18029469
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d rosuvastatin
Study: 15786754
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.07 mL/kg body weight/sec over 30 sec at an iodine concentration of 300 mgI/mL (Group 1)
Study: 15786754
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.06 mL/kg body weight/sec over 30 sec at an iodine concentration of 350 mgI/mL (Group 2)
Study: 15786754
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection at 0.07 mL/kg body weight/sec over 25.7 sec at an iodine concentration of 350 mgI/mL (Group 3)
Study: 10349120
Drug: Saline group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group: 0.45% saline solution I.V., 1.5 cc/kg/min, 6 hours before and after the angiographic study
Study: 10349120
Drug: Dopa group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopa group: 0.45% saline solution I.V. plus dopamine 2 micrograms/kg/min, 30 minutes before the study until termination
Study: 7756151
Drug: 0.05‐0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05‐0.1% tretinoin cream (Retin A, Ortho)
Study: 7756151
Drug: Purpose cream
Normalized name: Purpose Cream
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purpose cream (vehicle control)
Study: 2192553
Drug: Loperamide hydrochloride
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide hydrochloride (8 mg daily dosage limit, 40 ml)
Study: 2192553
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (4.9 g daily dosage limit)
Study: 794716
Drug: Naltrexone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone plus behavior therapy
Study: 31540724
Drug: Porcine dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine dermal patch augmentation
Study: 23070057
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day for 30 days)
Study: 15997021
Drug: Non-selective serotonin
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective serotonin reuptake inhibitor antidepressants
Study: 9491504
Drug: MN rgp160
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp160 vaccine (200 μg doses)
Study: 9491504
Drug: MN rgp160
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp160 vaccine (800 μg fourth dose)
Study: 9098468
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) treatment
Study: 2759843
Drug: Group administered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group administered CBT
Study: 2759843
Drug: Individually administered
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually administered CBT
Study: 2759843
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (wait list) control
Study: 29759063
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and NSAIDs (specific dosages and duration not mentioned)
Study: 25064723
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab (both treatments)
Study: 22774615
Drug: Shengjing Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengjing Tablets
Study: 22774615
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E capsules (control group)
Study: 8903629
Drug: Octreotide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (1 mu g/kg body weight subcutaneously, twice a day at 0800 and 1800 h)
Study: 2633238
Drug: Tablet pancreatin
Normalized name: pancreatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet pancreatin (12 tablets/day)
Study: 323298
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg triamterene plus 25 mg hydrochlorothiazide
Study: 323298
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg spironolactone plus 25 mg hydrochlorothiazide